[1] |
Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev, 2020, 40(1):263-292. doi: 10.1002/med.21602.
doi: 10.1002/med.21602
pmid: 31254295
|
[2] |
Keam SJ. Pretomanid: First Approval. Drugs, 2019, 79(16):1797-1803. doi: 10.1007/s40265-019-01207-9.
doi: 10.1007/s40265-019-01207-9
URL
|
[3] |
Burki T. BPaL approved for multidrug-resistant tuberculosis. Lancet Infect Dis, 2019, 19(10):1063-1064. doi: 10.1016/S1473-3099(19)30489-X.
doi: 10.1016/S1473-3099(19)30489-X
URL
|
[4] |
World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
|
[5] |
TB Alliance. Access to the BPaL Regimen[EB/OL]. [2021-11-15]. https://www.tballiance.org/access/countries.
|
[6] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814
URL
|
[7] |
TB Alliance. PRETOMANID tablets, for oral use[EB/OL]. [2021-11-15]. https://www.tballiance.org/sites/default/files/assets/Pretomanid_Full-Prescribing-Information.pdf.
|
[8] |
Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol, 2009, 2(3):215-218. doi: 10.4161/cib.2.3.7926.
doi: 10.4161/cib.2.3.7926
pmid: 19641733
|
[9] |
Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008, 322(5906):1392-1395. doi: 10.1126/science.1164571.
doi: 10.1126/science.1164571
URL
|
[10] |
Baptista R, Fazakerley DM, Beckmann M, et al. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Sci Rep, 2018, 8(1):5084. doi: 10.1038/s41598-018-23110-1.
doi: 10.1038/s41598-018-23110-1
pmid: 29572459
|
[11] |
Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2015, 59(9):5316-5323. doi: 10.1128/AAC.00308-15.
doi: 10.1128/AAC.00308-15
pmid: 26100695
|
[12] |
Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother, 2005, 49(6):2294-2301. doi: 10.1128/AAC.49.6.2294-2301.2005.
doi: 10.1128/AAC.49.6.2294-2301.2005
pmid: 15917524
|
[13] |
Zhang F, Li S, Wen S, et al. Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis. Infect Drug Resist, 2020, 13:815-822. doi: 10.2147/IDR.S240716.
doi: 10.2147/IDR.S240716
URL
|
[14] |
Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother, 2005, 49(6):2289-2293. doi: 10.1128/AAC.49.6.2289-2293.2005.
doi: 10.1128/AAC.49.6.2289-2293.2005
URL
|
[15] |
Lanoix JP, Betoudji F, Nuermberger E. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother, 2014, 58(4):2316-2321. doi: 10.1128/AAC.02658-13.
doi: 10.1128/AAC.02658-13
URL
|
[16] |
Tasneen R, Williams K, Amoabeng O, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother, 2015, 59(1):129-135. doi: 10.1128/AAC.03822-14.
doi: 10.1128/AAC.03822-14
pmid: 25331697
|
[17] |
Xu J, Li SY, Almeida DV, et al. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother, 2019, 63(5):e00021-19. doi: 10.1128/AAC.00021-19.
doi: 10.1128/AAC.00021-19
|
[18] |
Salinger DH, Subramoney V, Everitt D, et al. Population Pharmacokinetics of the Antituberculosis Agent Pretomanid. Antimicrob Agents Chemother, 2019, 63(10):e00907-19. doi: 10.1128/AAC.00907-19.
doi: 10.1128/AAC.00907-19
|
[19] |
Dooley KE, Luetkemeyer AF, Park JG, et al. Phase Ⅰ safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother, 2014, 58(9):5245-5252. doi: 10.1128/AAC.03332-14.
doi: 10.1128/AAC.03332-14
pmid: 24957823
|
[20] |
Diacon AH, Dawson R, du Bois J, et al. Phase Ⅱ dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012, 56(6):3027-3031. doi: 10.1128/AAC.06125-11.
doi: 10.1128/AAC.06125-11
URL
|
[21] |
Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet, 2015, 385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X.
doi: 10.1016/S0140-6736(14)62002-X
URL
|
[22] |
Diacon AH, Dawson R, von Groote-Bidlingmaier F , et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med, 2015, 191(8):943-953. doi: 10.1164/rccm.201410-1801OC.
doi: 10.1164/rccm.201410-1801OC
URL
|
[23] |
Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993. doi: 10.1016/S0140-6736(12)61080-0.
doi: 10.1016/S0140-6736(12)61080-0
URL
|
[24] |
Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis, 2018, 18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5.
doi: 10.1016/S1473-3099(18)30110-5
|
[25] |
TB Alliance. Pretomanid[EB/OL]. [2021-11-15]. https://www.tballiance.org/portfolio/compound/pretomanid.
|
[26] |
The Conference on Retroviruses and Opportunistic Infections. Final results of the Nix-TB clinical study of BPaL regimen for highly resistant TB[EB/OL]. [2021-11-15]. https://www.croiconference.org/abstract/final-results-of-the-nix-tb-clinical-study-of-bpal-regimen-for-highly-resistant-tb/.
|
[27] |
Conradie F, Everitt D, Olugbosi M, et al. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid[EB/OL]. [2021-11-15]. https://theprogramme.ias2021.org/Abstract/Abstract/2405.
|
[28] |
Médecins Sans Frontières. Drug-resistant TB clinical trial ends enrolment early after positive initial data[EB/OL]. [2021-11-15]. https://www.msf.org/drug-resistant-tuberculosis-trial-ends-enrolment-after-positive-initial-data.
|
[29] |
Tweed CD, Wills GH, Crook AM, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis, 2021, 25(4):305-314. doi: 10.5588/ijtld.20.0513.
doi: 10.5588/ijtld.20.0513
pmid: 33762075
|
[30] |
Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med, 2019, 7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2.
doi: 10.1016/S2213-2600(19)30366-2
URL
|
[31] |
Li M, Saviolakis GA, El-Amin W, et al. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination with Moxifloxacin, on the QTc Interval in Healthy Volunteers. Clin Pharmacol Drug Dev, 2021, 10(6):634-646. doi: 10.1002/cpdd.898.
doi: 10.1002/cpdd.898
URL
|
[32] |
World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
|
[33] |
复星医药. 复星医药获TB Alliance药物独家授权[EB/OL]. [2021-11-15]. https://www.fosunpharma.com/news/news-details-2251.html.
|
[34] |
初乃惠. 以时不我待的精神探索中国耐药肺结核患者全口服化学治疗方案. 中国防痨杂志, 2021, 43(9):857-858. doi: 10.3969/j.issn.1000-6621.2021.09.001.
doi: 10.3969/j.issn.1000-6621.2021.09.001
|